Literature DB >> 17578783

The challenges posed by reemerging Clostridium difficile infection.

David B Blossom1, L Clifford McDonald.   

Abstract

There have been recent, marked increases in the incidence and severity of Clostridium difficile-associated disease (CDAD). These may be attributable to the emergence of a hypervirulent strain of C. difficile that produces increased levels of toxins A and B, as well as an extra toxin known as "binary toxin." This previously uncommon strain has become epidemic, coincident with its development of increased resistance to fluoroquinolones, the use of which is increasingly associated with CDAD outbreaks. Although not necessarily related to this epidemic strain, unusually severe CDAD has been reported in populations that had previously been thought to be at low risk, including peripartum women and healthy persons living in the community. Challenges posed by the changing epidemiology of CDAD are compounded by current limitations in diagnostic testing, treatment, and infection control. Overcoming these challenges and limitations will require a concerted effort from a variety of sources, including an ongoing partnership between infectious disease clinicians and public health professionals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17578783     DOI: 10.1086/518874

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  45 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

2.  Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models.

Authors:  Jennifer Steele; Kevin Chen; Xingmin Sun; Yongrong Zhang; Haiying Wang; Saul Tzipori; Hanping Feng
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

3.  Evaluation of two rapid immunochromatography tests for the detection of Clostridium difficile toxins.

Authors:  Zmira Samra; Avia Luzon; Jihad Bishara
Journal:  Dig Dis Sci       Date:  2007-11-08       Impact factor: 3.199

4.  Management of severe Clostridium difficile-associated diarrhea.

Authors:  Michael J Krier; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2009-02-19       Impact factor: 3.199

Review 5.  Clostridium difficile infection: molecular pathogenesis and novel therapeutics.

Authors:  Ardeshir Rineh; Michael J Kelso; Fatma Vatansever; George P Tegos; Michael R Hamblin
Journal:  Expert Rev Anti Infect Ther       Date:  2014-01       Impact factor: 5.091

6.  Gastrointestinal colonization with a cephalosporinase-producing bacteroides species preserves colonization resistance against vancomycin-resistant enterococcus and Clostridium difficile in cephalosporin-treated mice.

Authors:  Usha Stiefel; Michelle M Nerandzic; Michael J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

Review 7.  Physical, Laboratory, Radiographic, and Endoscopic Workup for Clostridium difficile Colitis.

Authors:  Samantha J Baker; Daniel I Chu
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

8.  Bowel preparation for colectomy and risk of Clostridium difficile infection.

Authors:  Greta L Krapohl; Laurel R S Phillips; Darrell A Campbell; Samantha Hendren; Mousumi Banerjee; Bonnie Metzger; Arden M Morris
Journal:  Dis Colon Rectum       Date:  2011-07       Impact factor: 4.585

9.  A novel subtyping assay for detection of Clostridium difficile virulence genes.

Authors:  Stephanie L Angione; Aartik A Sarma; Aleksey Novikov; Leah Seward; Jennifer H Fieber; Leonard A Mermel; Anubhav Tripathi
Journal:  J Mol Diagn       Date:  2014-01-13       Impact factor: 5.568

10.  Metabolism of bile salts in mice influences spore germination in Clostridium difficile.

Authors:  Jennifer L Giel; Joseph A Sorg; Abraham L Sonenshein; Jun Zhu
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.